A New Drug Change The Human Tumor Metabolite

Researchers from University of Texas MD Anderson cancer center have indicated that altering tumor suppressor gene p53 family members may induce rapid regression of tumors lack of p53. This study was published in Nature.

TP53 is commonly altered in human cancer and the Tp53 reactivation suppresses tumors in vivo in mice (TP53 and Tp53 are also known as p53). This strategy has proven difficult to implement therapeutically.

In this study, scientists try to examine an alternative strategy by manipulating the p53 family members, Tp63 and Tp73 (also known as p63 and p73). The acidic transactivation-domain bearing (TA) isoforms of p63 and p73 structurally and functionally resemble p53, whereas the?N isoforms of p63 and p73 are frequently overexpressed in cancer and act primarily in a dominant-negative fashion against p53, TAp63 and TAp73 to inhibit their tumour-supressive functions. The researchers have shown that the deletion of?N isoforms of p63 or p73 leads to metabolic reprogramming and regression of p53-deficient tumours through upregualtion of IAPP, the gene that encodes amylin.

In addition, they found that IAPP is causally involved in this tumor regression and that amylin functions through the calcitonin receptor (CalcR) and receptor activity modifying protein 3 (RAMP3) to inhibit glycolysis and induce reactive oxygen species and apoptosis.

This study provides new insight of targeting tumors which are lack of p53 or with p53 mutation. Meanwhile, the researchers also identify the key receptors of cancer cells which are eliminated of p53 gene. These receptors may be potential prognostic markers to ensure if pramlintide will be effective to cure the patients with p53 mutation or lack of p53.

The Manchester scientists found a new drug, and the new drug can inhibit the tumor growth. The new drug, together with the radiation therapy, could be applied for effective treatment of tumor in the clinical.

In the process of tumor cell metabolism, the lactic acid was produced. The Lactic acid cause toxicity to tumor cells, so the lactic acid must be transferred by the molecular transporters (MCT) out of tumor cells. Astrazeneca pharmaceutical drug-AZD3965 inhibited a MCT1 in lung cancer cells. Researchers of the Manchester investigated the therapeutic effect of the drug combined with radiotherapy. The further study confirmed that the new drug, together with the radiation therapy, could be applied for effective treatment of tumor in the clinical.

Professor Ian Stratford said AZD3965 can inhibit MCT1, specifically targeting tumor by tumor metabolism. This drug was used as a single drug test in clinical trials. And he has shown that the drug combined with radiotherapy could be the new treatment of cancer patients.

Numerologist Warda is hooked on OG-L002 fishing, collecting. And lastly her encouragement comes from socializing along with her companions.